Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company was founded in 1990 and is based in Ness Ziona, Israel.
KMDA Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Kamada Ltd. To summarize, we found that Kamada Ltd ranked in the 98th percentile in terms of potential gain offered. Our DCF analysis implies the stock could yield a return of 25692.17% if fairly valued; such returns are always unlikely, though, so further investigation is likely warranted. In terms of the factors that were most noteworthy in this DCF analysis for KMDA, they are:
As a business, KMDA is generating more cash flow than only 23.81% of positive cash flow stocks in the Healthcare.
The business' balance sheet reveals debt to be 2% of the company's capital (with equity being the remaining amount). Approximately just 7.51% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
KMDA's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 54.92% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
NVCR, VRTX, OMI, USNU, and CORT can be thought of as valuation peers to KMDA, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
At this time, I will turn the conference over to Bob Yedid with LifeSci Advisors. Good morning, this is Bob Yedid with LifeSci Advisors. Joining me from Kamada are Amir London, Chief Executive Officer; and Chaime Orlev, Chief Financial Officer.
Shares of Kamada (NASDAQ:KMDA) were flat in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share were unchanged 0.00% year over year to $0.12, which beat the estimate of $0.06.Revenue of $33,290,000 rose by 24.23% year over year, which beat the estimate of $30,120,000.Outlook Kamada hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.Conference Call Details Date: May 18, 2020View more earnings on KMDATime: 08:30 AMET Webcast URL: https://www.kamada.com/events-presentations/Recent Stock Performance Company's 52-week high was at $8.00Company's 52-week low was at $4.40Price action over last quarter: Up 14.17%Company Description Kamada Ltd is a drug-focused, plasma-derived protein therapeu...
Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the first quarter ended March 31, 2020, prior to the open of the U.S. financial markets on Monday, May 18, 2020. Kamada management will host an investment community conference call on Monday, May 18, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel), or 201-689-8263 (International) and entering the conference identification number: 13699990.